Position in MYGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$129,447
New position
Shares Held
28,766
first reported quarter
Ownership
0.030%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026Quadrature Capital Ltd holds $1,206,303 across 6 Diagnostics & Research names. MYGN ranks #5 (10.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | FLGT |
Fulgent Genetics, Inc.
|
19,640 | $312,276 | |
| 2 | PSNL |
Personalis, Inc.
|
38,722 | $246,659 | |
| 3 | VCYT |
Veracyte, Inc.
|
7,594 | $244,602 | |
| 4 | ADPT |
Adaptive Biotechnologies Corp
|
12,387 | $171,931 | |
| 5 | MYGN |
Myriad Genetics Inc
This page
|
28,766 | $129,447 | |
| 6 | OPK |
Opko Health, Inc.
|
88,937 | $101,388 |
All Filings in MYGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $129,447 | 28,766 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||